DOCSLIB.ORG

Mouse Rasgrf2 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

https://www.alphaknockout.com Mouse Rasgrf2 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Rasgrf2 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Rasgrf2 gene (NCBI Reference Sequence: NM_009027 ; Ensembl: ENSMUSG00000021708 ) is located on Mouse chromosome 13. 34 exons are identified, with the ATG start codon in exon 1 and the GGT stop codon in exon 34 (Transcript: ENSMUST00000099326). Exon 2 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Rasgrf2 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP24-270O23 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a targeted null mutation exhibit decreased Il2 and TNF-alpha production in stimulated T cells. Mice homozygous for mutations in both Rasgrf1 and Rasgrf2 exhibit no additional abnormalities than those observed in the Rasgrf1 mutant mice. Exon 2 starts from about 8.11% of the coding region. The knockout of Exon 2 will result in frameshift of the gene. The size of intron 1 for 5'-loxP site insertion: 77551 bp, and the size of intron 2 for 3'-loxP site insertion: 15224 bp. The size of effective cKO region: ~607 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 2 34 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Rasgrf2 Homology arm cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(7107bp) | A(27.11% 1927) | C(21.33% 1516) | T(30.07% 2137) | G(21.49% 1527) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 7 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr13 - 92053906 92056905 3000 browser details YourSeq 194 1198 1575 3000 85.2% chr15 - 37609088 37609467 380 browser details YourSeq 190 1198 1587 3000 87.1% chr17 + 85673891 85674296 406 browser details YourSeq 181 1251 1584 3000 83.8% chr11 + 80306740 80307071 332 browser details YourSeq 179 1198 1594 3000 85.5% chr5 - 134150272 134150751 480 browser details YourSeq 179 1199 1594 3000 87.8% chr18 + 53403690 53593664 189975 browser details YourSeq 172 1205 1576 3000 83.4% chr6 - 6061776 6062141 366 browser details YourSeq 167 1198 1584 3000 83.4% chr14 - 66897956 66898359 404 browser details YourSeq 161 1198 1591 3000 86.8% chr5 + 35309146 35309581 436 browser details YourSeq 159 1198 1572 3000 82.6% chrX - 150945410 150945774 365 browser details YourSeq 159 1225 1550 3000 84.4% chr11 - 109530613 109530941 329 browser details YourSeq 158 1242 1584 3000 85.3% chr5 + 99389273 99389617 345 browser details YourSeq 157 1198 1584 3000 88.7% chr7 + 122795983 122796372 390 browser details YourSeq 155 1177 1493 3000 86.4% chr10 + 43616379 43616749 371 browser details YourSeq 153 1302 1590 3000 84.9% chr5 + 113488803 113489092 290 browser details YourSeq 152 1198 1591 3000 88.4% chr9 - 9076165 9076558 394 browser details YourSeq 151 1338 1594 3000 86.8% chr13 + 64409812 64410075 264 browser details YourSeq 150 1205 1454 3000 80.7% chr16 - 13043209 13043460 252 browser details YourSeq 150 1198 1572 3000 88.2% chr12 + 71443846 71444212 367 browser details YourSeq 147 1198 1573 3000 86.9% chr4 - 141557163 141557759 597 Note: The 3000 bp section upstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr13 - 92050299 92053298 3000 browser details YourSeq 159 458 835 3000 87.8% chr13 - 73967680 73968062 383 browser details YourSeq 150 442 758 3000 83.7% chr7 - 34917191 34917496 306 browser details YourSeq 134 497 762 3000 89.9% chr17 - 28663868 28845010 181143 browser details YourSeq 130 457 813 3000 71.8% chr17 + 26862493 26862846 354 browser details YourSeq 129 482 726 3000 89.1% chr10 + 95110321 95110573 253 browser details YourSeq 129 486 825 3000 91.7% chr1 + 92884356 92884700 345 browser details YourSeq 126 500 726 3000 89.9% chr13 - 60530509 60530740 232 browser details YourSeq 126 458 663 3000 88.2% chr3 + 34117257 34117450 194 browser details YourSeq 121 501 825 3000 84.7% chr4 - 138631261 138631578 318 browser details YourSeq 118 457 663 3000 91.7% chr11 - 116301949 116302161 213 browser details YourSeq 117 465 813 3000 91.0% chr1 + 90307687 90308044 358 browser details YourSeq 113 459 663 3000 90.1% chr8 - 82736300 82736504 205 browser details YourSeq 112 498 663 3000 92.5% chr11 + 32014725 32014897 173 browser details YourSeq 110 491 663 3000 86.6% chr1 - 89808511 89808683 173 browser details YourSeq 110 500 662 3000 90.6% chr11 + 117037685 117037850 166 browser details YourSeq 109 500 831 3000 91.7% chr17 - 29866828 29867164 337 browser details YourSeq 108 476 656 3000 92.3% chrX - 51230367 51230549 183 browser details YourSeq 108 548 823 3000 88.6% chr3 - 34507689 34508397 709 browser details YourSeq 107 497 663 3000 89.2% chr14 - 15693835 15694000 166 Note: The 3000 bp section downstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. Page 4 of 7 https://www.alphaknockout.com Gene and protein information: Rasgrf2 RAS protein-specific guanine nucleotide-releasing factor 2 [ Mus musculus (house mouse) ] Gene ID: 19418, updated on 12-Aug-2019 Gene summary Official Symbol Rasgrf2 provided by MGI Official Full Name RAS protein-specific guanine nucleotide-releasing factor 2 provided by MGI Primary source MGI:MGI:109137 See related Ensembl:ENSMUSG00000021708 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as Grf2; AW048350; Ras-GRF2; 6330417G04Rik Annotation Annotation category: suggests misassembly information Annotation category: partial on reference assembly Expression Biased expression in frontal lobe adult (RPKM 11.9), cortex adult (RPKM 11.9) and 14 other tissues See more Orthologs human all Genomic context Location: 13 C3; 13 47.43 cM See Rasgrf2 in Genome Data Viewer Exon count: 26 Annotation Status Assembly Chr Location release GRCm38.p6 108 current 13 NC_000079.6 (91880407..92131828, complement) (GCF_000001635.26) previous MGSCv37 NC_000079.5 (92792695..92901449, complement) , Build 37.2 13 assembly (GCF_000001635.18) (92020012..92127647, complement) Chromosome 13 - NC_000079.6 Page 5 of 7 https://www.alphaknockout.com Transcript information: This gene has 6 transcripts Gene: Rasgrf2 ENSMUSG00000021708 Description RAS protein-specific guanine nucleotide-releasing factor 2 [Source:MGI Symbol;Acc:MGI:109137] Gene Synonyms 6330417G04Rik, Grf2 Location Chromosome 13: 91,880,400-92,131,656 reverse strand. GRCm38:CM001006.2 About this gene This gene has 6 transcripts (splice variants), 256 orthologues, 39 paralogues, is a member of 1 Ensembl protein family and is associated with 2 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Rasgrf2-205 ENSMUST00000151408.7 5797 588aa ENSMUSP00000116892.1 Protein coding - F7B9R2 CDS 5' incomplete TSL:1 Rasgrf2-201 ENSMUST00000099326.9 3567 1188aa ENSMUSP00000096930.3 Protein coding - D3Z6K8 TSL:5 GENCODE basic APPRIS P1 Rasgrf2-206 ENSMUST00000216219.1 2115 505aa ENSMUSP00000149731.1 Protein coding - A0A1L1SS23 TSL:5 GENCODE basic Rasgrf2-202 ENSMUST00000142378.1 1789 252aa ENSMUSP00000115401.1 Protein coding - F6TYF8 CDS 5' incomplete TSL:1 Rasgrf2-203 ENSMUST00000146492.2 1323 387aa ENSMUSP00000116203.1 Protein coding - D3Z685 CDS 3' incomplete TSL:5 Rasgrf2-204 ENSMUST00000149630.7 502 168aa ENSMUSP00000115562.1 Protein coding - F6TCD3 CDS 5' and 3' incomplete TSL:5 271.26 kb Forward strand 91.9Mb 92.0Mb 92.1Mb Contigs AC167972.3 > < AC164622.3 AC146698.10 > Genes (Comprehensive set... < Ckmt2-201protein coding < Rasgrf2-202protein coding < Rasgrf2-206protein coding < Rasgrf2-205protein coding < Rasgrf2-203protein coding < Rasgrf2-201protein coding < Rasgrf2-204protein coding Regulatory Build 91.9Mb 92.0Mb 92.1Mb Reverse strand 271.26 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Transcription Factor Binding Site Gene Legend Protein Coding Ensembl protein coding merged Ensembl/Havana Page 6 of 7 https://www.alphaknockout.com
Recommended publications
  • Functional Parsing of Driver Mutations in the Colorectal Cancer Genome Reveals Numerous Suppressors of Anchorage-Independent

    Functional Parsing of Driver Mutations in the Colorectal Cancer Genome Reveals Numerous Suppressors of Anchorage-Independent

    Supplementary information Functional parsing of driver mutations in the colorectal cancer genome reveals numerous suppressors of anchorage-independent growth Ugur Eskiocak1, Sang Bum Kim1, Peter Ly1, Andres I. Roig1, Sebastian Biglione1, Kakajan Komurov2, Crystal Cornelius1, Woodring E. Wright1, Michael A. White1, and Jerry W. Shay1. 1Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9039. 2Department of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77054. Supplementary Figure S1. K-rasV12 expressing cells are resistant to p53 induced apoptosis. Whole-cell extracts from immortalized K-rasV12 or p53 down regulated HCECs were immunoblotted with p53 and its down-stream effectors after 10 Gy gamma-radiation. ! Supplementary Figure S2. Quantitative validation of selected shRNAs for their ability to enhance soft-agar growth of immortalized shTP53 expressing HCECs. Each bar represents 8 data points (quadruplicates from two separate experiments). Arrows denote shRNAs that failed to enhance anchorage-independent growth in a statistically significant manner. Enhancement for all other shRNAs were significant (two tailed Studentʼs t-test, compared to none, mean ± s.e.m., P<0.05)." ! Supplementary Figure S3. Ability of shRNAs to knockdown expression was demonstrated by A, immunoblotting for K-ras or B-E, Quantitative RT-PCR for ERICH1, PTPRU, SLC22A15 and SLC44A4 48 hours after transfection into 293FT cells. Two out of 23 tested shRNAs did not provide any knockdown. " ! Supplementary Figure S4. shRNAs against A, PTEN and B, NF1 do not enhance soft agar growth in HCECs without oncogenic manipulations (Student!s t-test, compared to none, mean ± s.e.m., ns= non-significant).
  • Bioinformatics Analyses of Genomic Imprinting

    Bioinformatics Analyses of Genomic Imprinting

    Bioinformatics Analyses of Genomic Imprinting Dissertation zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Barbara Hutter Saarbrücken 2009 Tag des Kolloquiums: 08.12.2009 Dekan: Prof. Dr.-Ing. Stefan Diebels Berichterstatter: Prof. Dr. Volkhard Helms Priv.-Doz. Dr. Martina Paulsen Vorsitz: Prof. Dr. Jörn Walter Akad. Mitarbeiter: Dr. Tihamér Geyer Table of contents Summary________________________________________________________________ I Zusammenfassung ________________________________________________________ I Acknowledgements _______________________________________________________II Abbreviations ___________________________________________________________ III Chapter 1 – Introduction __________________________________________________ 1 1.1 Important terms and concepts related to genomic imprinting __________________________ 2 1.2 CpG islands as regulatory elements ______________________________________________ 3 1.3 Differentially methylated regions and imprinting clusters_____________________________ 6 1.4 Reading the imprint __________________________________________________________ 8 1.5 Chromatin marks at imprinted regions___________________________________________ 10 1.6 Roles of repetitive elements ___________________________________________________ 12 1.7 Functional implications of imprinted genes _______________________________________ 14 1.8 Evolution and parental conflict ________________________________________________
  • Molecular Effects of Isoflavone Supplementation Human Intervention Studies and Quantitative Models for Risk Assessment

    Molecular Effects of Isoflavone Supplementation Human Intervention Studies and Quantitative Models for Risk Assessment

    Molecular effects of isoflavone supplementation Human intervention studies and quantitative models for risk assessment Vera van der Velpen Thesis committee Promotors Prof. Dr Pieter van ‘t Veer Professor of Nutritional Epidemiology Wageningen University Prof. Dr Evert G. Schouten Emeritus Professor of Epidemiology and Prevention Wageningen University Co-promotors Dr Anouk Geelen Assistant professor, Division of Human Nutrition Wageningen University Dr Lydia A. Afman Assistant professor, Division of Human Nutrition Wageningen University Other members Prof. Dr Jaap Keijer, Wageningen University Dr Hubert P.J.M. Noteborn, Netherlands Food en Consumer Product Safety Authority Prof. Dr Yvonne T. van der Schouw, UMC Utrecht Dr Wendy L. Hall, King’s College London This research was conducted under the auspices of the Graduate School VLAG (Advanced studies in Food Technology, Agrobiotechnology, Nutrition and Health Sciences). Molecular effects of isoflavone supplementation Human intervention studies and quantitative models for risk assessment Vera van der Velpen Thesis submitted in fulfilment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. Dr M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Friday 20 June 2014 at 13.30 p.m. in the Aula. Vera van der Velpen Molecular effects of isoflavone supplementation: Human intervention studies and quantitative models for risk assessment 154 pages PhD thesis, Wageningen University, Wageningen, NL (2014) With references, with summaries in Dutch and English ISBN: 978-94-6173-952-0 ABSTRact Background: Risk assessment can potentially be improved by closely linked experiments in the disciplines of epidemiology and toxicology.
  • Supporting Information

    Supporting Information

    Supporting Information Tirard et al. 10.1073/pnas.1215366110 SI Materials and Methods 4 mM Hepes (pH 7.4), protease inhibitors (1 μg/mL aprotinin, μ μ Generation of His6-HA-SUMO1 KI Mice. A 15-kbp SV129 mouse 0.5 g/mL leupeptine, and 17.4 g/mL PMSF), and 20 mM N- genomic fragment containing exon 1 of the SUMO1 gene and ethylmaleimide (NEM). flanking sequences was isolated from a λFIXII genomic library (Stratagene) (Fig. S1A). A 3-kbp fragment containing exon 1 of Immunoblotting and Quantitative Western Blot Analysis. SDS/PAGE the SUMO1 gene was subcloned into pBluescript. The His -HA was performed with standard discontinuous gels or with com- 6 – double tag was inserted in frame 3′ of the start codon using PCR mercially available 4 12% (wt/vol) Bis-Tris gradient gels (In- with engineered primers. The mutated fragment was then ex- vitrogen). Western blots were probed using primary and secondary cised with XbaI and inserted into the NheI site of the targeting antibodies as indicated in Tables S1 and S2. Blots were routinely vector pTKNeoLox. For the long arm, a SmaI/BamHI fragment developed using enhanced chemiluminescence (GE Healthcare). of 5 kbp was excised from the genomic clone and inserted into For quantitative Western blotting, transferred proteins were vi- the NsiI/BamHI sites of the targeting vector. The final construct sualized by Fast Green FCF (Sigma) staining of the membrane. contained two copies of the HSV thymidine kinase gene, a short Corresponding images were taken with an Odyssey reader (LI- arm containing the tagged exon 1, a neomycin resistance cassette COR) using the 700-nm channel and used for the normalization flanked by two loxP sites, and a long arm (Fig.
  • Systematic Elucidation of Neuron-Astrocyte Interaction in Models of Amyotrophic Lateral Sclerosis Using Multi-Modal Integrated Bioinformatics Workflow

    Systematic Elucidation of Neuron-Astrocyte Interaction in Models of Amyotrophic Lateral Sclerosis Using Multi-Modal Integrated Bioinformatics Workflow

    ARTICLE https://doi.org/10.1038/s41467-020-19177-y OPEN Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow Vartika Mishra et al.# 1234567890():,; Cell-to-cell communications are critical determinants of pathophysiological phenotypes, but methodologies for their systematic elucidation are lacking. Herein, we propose an approach for the Systematic Elucidation and Assessment of Regulatory Cell-to-cell Interaction Net- works (SEARCHIN) to identify ligand-mediated interactions between distinct cellular com- partments. To test this approach, we selected a model of amyotrophic lateral sclerosis (ALS), in which astrocytes expressing mutant superoxide dismutase-1 (mutSOD1) kill wild-type motor neurons (MNs) by an unknown mechanism. Our integrative analysis that combines proteomics and regulatory network analysis infers the interaction between astrocyte-released amyloid precursor protein (APP) and death receptor-6 (DR6) on MNs as the top predicted ligand-receptor pair. The inferred deleterious role of APP and DR6 is confirmed in vitro in models of ALS. Moreover, the DR6 knockdown in MNs of transgenic mutSOD1 mice attenuates the ALS-like phenotype. Our results support the usefulness of integrative, systems biology approach to gain insights into complex neurobiological disease processes as in ALS and posit that the proposed methodology is not restricted to this biological context and could be used in a variety of other non-cell-autonomous communication
  • Robles JTO Supplemental Digital Content 1

    Robles JTO Supplemental Digital Content 1

    Supplementary Materials An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma based on mRNA, microRNA and DNA Methylation Biomarkers Ana I. Robles1, Eri Arai2, Ewy A. Mathé1, Hirokazu Okayama1, Aaron Schetter1, Derek Brown1, David Petersen3, Elise D. Bowman1, Rintaro Noro1, Judith A. Welsh1, Daniel C. Edelman3, Holly S. Stevenson3, Yonghong Wang3, Naoto Tsuchiya4, Takashi Kohno4, Vidar Skaug5, Steen Mollerup5, Aage Haugen5, Paul S. Meltzer3, Jun Yokota6, Yae Kanai2 and Curtis C. Harris1 Affiliations: 1Laboratory of Human Carcinogenesis, NCI-CCR, National Institutes of Health, Bethesda, MD 20892, USA. 2Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo 104-0045, Japan. 3Genetics Branch, NCI-CCR, National Institutes of Health, Bethesda, MD 20892, USA. 4Division of Genome Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan. 5Department of Chemical and Biological Working Environment, National Institute of Occupational Health, NO-0033 Oslo, Norway. 6Genomics and Epigenomics of Cancer Prediction Program, Institute of Predictive and Personalized Medicine of Cancer (IMPPC), 08916 Badalona (Barcelona), Spain. List of Supplementary Materials Supplementary Materials and Methods Fig. S1. Hierarchical clustering of based on CpG sites differentially-methylated in Stage I ADC compared to non-tumor adjacent tissues. Fig. S2. Confirmatory pyrosequencing analysis of DNA methylation at the HOXA9 locus in Stage I ADC from a subset of the NCI microarray cohort. 1 Fig. S3. Methylation Beta-values for HOXA9 probe cg26521404 in Stage I ADC samples from Japan. Fig. S4. Kaplan-Meier analysis of HOXA9 promoter methylation in a published cohort of Stage I lung ADC (J Clin Oncol 2013;31(32):4140-7). Fig. S5. Kaplan-Meier analysis of a combined prognostic biomarker in Stage I lung ADC.
  • DNA Methylation of Developmental Genes in Pediatric Medulloblastomas Identified by Denaturation Analysis of Methylation Differences

    DNA Methylation of Developmental Genes in Pediatric Medulloblastomas Identified by Denaturation Analysis of Methylation Differences

    DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences Scott J. Diedea,b, Jamie Guenthoerc, Linda N. Gengc, Sarah E. Mahoneyc, Michael Marottad,e, James M. Olsona,b, Hisashi Tanakad,e, and Stephen J. Tapscotta,c,1 Divisions of aClinical Research and cHuman Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; bDepartment of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195; dDepartment of Molecular Genetics, Cleveland Clinic, Cleveland, OH 44195; and eLerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 Edited by Mark T. Groudine, Fred Hutchinson Cancer Research Center, Seattle, WA, and approved November 6, 2009 (received for review July 8, 2009) DNA methylation might have a significant role in preventing normal Results differentiation in pediatric cancers. We used a genomewide method An Assay to Detect Palindrome Formation Enriches for CpG Methylation. for detecting regions of CpG methylation on the basis of the in- Earlier work from our laboratory focused on identifying regions of creased melting temperature of methylated DNA, termed denatu- the genome susceptible to DNA palindrome formation, a rate- ration analysis of methylation differences (DAMD). Using the DAMD limiting step in gene amplification. We previously described a fi fi assay, we nd common regions of cancer-speci c methylation method to obtain a genomewide analysis of palindrome formation changes in primary medulloblastomas in critical developmental reg- (GAPF) on the basis of the efficient intrastrand base pairing in ulatory pathways, including Sonic hedgehog (Shh), Wingless (Wnt), large palindromic sequences (3). Palindromic sequences can rap- retinoic acid receptor (RAR), and bone morphogenetic protein idly anneal intramolecularly to form “snap-back” DNA under (BMP).
  • Aberrant Hypomethylated KRAS and RASGRF2 As a Candidate

    Aberrant Hypomethylated KRAS and RASGRF2 As a Candidate

    Biom lar ark cu er e s l Yang et al., J Mol Biomark Diagn 2014, 5:5 o & M D f i a DOI: 10.4172/2155-9929.1000195 o g l Journal of Molecular Biomarkers n a o n r s i u s o J ISSN: 2155-9929 & Diagnosis Research Article Open Access Aberrant Hypomethylated KRAS and RASGRF2 as a Candidate Biomarker of Low Level Benzene Hematotoxicity Jing Yang1,2#, Wenlin Bai1,2#, Zhongxin Xiao3#, Yujiao Chen1,2, Li Chen1,2, Lefeng Zhang1,2, Junxiang Ma1,2, Lin Tian1,2 and Ai Gao1,2* 1Department of Occupational Health and Environmental Health, School of Public Health, Capital Medical University, Beijing 100069, P.R.China 2Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, P.R.China 3Center of Medical Experiment and Analysis, Capital Medical University, Beijing 100069, P.R.China #These authors contributed equally to this work Abstract Benzene is an important industrial chemical and an environmental contaminant. The mechanisms of low level benzene-induced hematotoxicity are unresolved. Aberrant DNA methylation, which may lead to genomic instability and the altered gene expression, is frequently observed in hematological cancers. The purpose of the present study was to conduct a genome-wide investigation to examine comprehensively whether low level benzene induces DNA methylation alteration in the benzene-exposed workers. Infinium 450K methylation array was used to compare methylation levels of the low level benzene-exposed individuals and health controls and the differentially expressed DNA methylation pattern critical for benzene hematotoxicity were screened. Signal net analysis showed that two key hypomethylated KRAS and RASGRF2 associated with low level benzene exposure were identified.
  • Datasheet: VMA00040K Product Details

    Datasheet: VMA00040K Product Details

    Datasheet: VMA00040K Description: H-RAS ANTIBODY WITH LYSATE CONTROL Specificity: H-RAS Other names: p21Ras Format: Purified Product Type: PrecisionAb™ Monoclonal Isotype: IgG1 Quantity: 10 Westerns Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Western Blotting 1/1000 PrecisionAb antibodies have been extensively validated for the western blot application. The antibody has been validated at the suggested dilution. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Further optimization may be required dependant on sample type. Target Species Human Species Cross Reacts with: Rat, Mouse Reactivity N.B. Antibody reactivity and working conditions may vary between species. Product Form Purified IgG - liquid Preparation 100μl Mouse monoclonal antibody purified by affinity chromatography on Protein A from ascites Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN3) Stabilisers Immunogen Synthetic peptide corresponding to amino acids DIHQYREQIKRVKDSDDC of human H-Ras External Database Links UniProt: P01112 Related reagents Entrez Gene: 3265 HRAS Related reagents Page 1 of 3 Synonyms HRAS1 Specificity Mouse anti Human H-Ras antibody recognizes the human GTPase H-Ras also known as H-Ras, transforming protein p21 or p21ras. H-Ras is a ubiquitously expressed lipid-anchored GTPase belonging to the Ras superfamily of small GTPases, which acts as a molecular signal transduction on/off switch on the inner surface of the plasma membrane and endomembranes (Milburn et al.
  • Genome-Wide Association Study and Pathway Analysis for Female Fertility Traits in Iranian Holstein Cattle

    Genome-Wide Association Study and Pathway Analysis for Female Fertility Traits in Iranian Holstein Cattle

    Ann. Anim. Sci., Vol. 20, No. 3 (2020) 825–851 DOI: 10.2478/aoas-2020-0031 GENOME-WIDE ASSOCIATION STUDY AND PATHWAY ANALYSIS FOR FEMALE FERTILITY TRAITS IN IRANIAN HOLSTEIN CATTLE Ali Mohammadi1, Sadegh Alijani2♦, Seyed Abbas Rafat2, Rostam Abdollahi-Arpanahi3 1Department of Genetics and Animal Breeding, University of Tabriz, Tabriz, Iran 2Department of Animal Science, Faculty of Agriculture, University of Tabriz, Tabriz, Iran 3Department of Animal Science, University College of Abureyhan, University of Tehran, Tehran, Iran ♦Corresponding author: [email protected] Abstract Female fertility is an important trait that contributes to cow’s profitability and it can be improved by genomic information. The objective of this study was to detect genomic regions and variants affecting fertility traits in Iranian Holstein cattle. A data set comprised of female fertility records and 3,452,730 pedigree information from Iranian Holstein cattle were used to predict the breed- ing values, which were then employed to estimate the de-regressed proofs (DRP) of genotyped animals. A total of 878 animals with DRP records and 54k SNP markers were utilized in the ge- nome-wide association study (GWAS). The GWAS was performed using a linear regression model with SNP genotype as a linear covariate. The results showed that an SNP on BTA19, ARS-BFGL- NGS-33473, was the most significant SNP associated with days from calving to first service. In total, 69 significant SNPs were located within 27 candidate genes. Novel potential candidate genes include OSTN, DPP6, EphA5, CADPS2, Rfc1, ADGRB3, Myo3a, C10H14orf93, KIAA1217, RBPJL, SLC18A2, GARNL3, NCALD, ASPH, ASIC2, OR3A1, CHRNB4, CACNA2D2, DLGAP1, GRIN2A and ME3.
  • Affiliations

    Affiliations

    bioRxiv preprint doi: https://doi.org/10.1101/286559; this version posted March 23, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Identification and prioritization of gene sets associated with schizophrenia risk by co- expression network analysis in human brain Eugenia Radulescu M.D., Ph.Da, Andrew E Jaffe Ph.Da,b,c,d, Richard E Straub Ph.Da, Qiang Chen Ph.Da, Joo Heon Shin Ph.Da, Thomas M Hyde M.D., Ph.Da,e,f, Joel E Kleinman M.D., Ph.Da,e, Daniel R Weinberger M.D.a,f,g,h,1 Affiliations: a. Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, 21205, USA b. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA c. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA d. Center for Computational Biology, Johns Hopkins University, Baltimore MD 21205 USA e. Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA f. Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA g. Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA h. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA 1Address correspondence to: Daniel R. Weinberger Lieber Institute for Brain Development Johns Hopkins Medicine 855 North Wolfe Street Baltimore, Maryland 21205 410-955-1000 ([email protected]) bioRxiv preprint doi: https://doi.org/10.1101/286559; this version posted March 23, 2018.
  • CEBPA (CCAAT Enhancer Binding Protein Alpha) (19Q13.1)

    CEBPA (CCAAT Enhancer Binding Protein Alpha) (19Q13.1)

    Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 10, Number 4, Oct-Dec2006 Previous Issue / Next Issue Genes JARID1A (Jumonji, AT rich interactive domain 1A (RBBP2-like)) (12p13). Laura JCM van Zutven, Anne RM von Bergh. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 460-465. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/JARID1AID41033ch12p13.html SS18 (synovial sarcoma translocation, chromosome 18) (18q11.2). Mamoru Ouchida. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 466-470. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/SS18ID84ch18q11.html PDE4DIP (phosphodiesterase 4D interacting protein (myomegalin)) (1q22). Jean Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 471-475. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PDE4DIP01q22ID180.html MYST4 (MYST histone acetyltransferase (monocytic leukemia) 4) (10q22.2). José Luis Vizmanos. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 476-483. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/MYST4ID41488ch10q22.html CRTC1 (CREB regulated transcription coactivator 1) (19p13.11) - updated. Afrouz Behboudi, Gôran Stenman. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 484-489. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/CRTC1ID471ch19p13.html CEBPA (CCAAT enhancer binding protein alpha) (19q13.1). Lan-Lan Smith. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 490-501.